Previous 10 | Next 10 |
AVEO Pharmaceuticals (AVEO): Q4 GAAP EPS of -$0.44 misses by $0.06.Revenue of $0.89M (+17.1% Y/Y) misses by $2.11M.Ended 2020 with $61.8 million in cash, cash equivalents, and marketable securities as compared with $47.7 million at December 31, 2019.Guidance: AVEO believes that its $61.8...
– FOTIVDA ® (tivozanib) Approved for Adult Patients with Relapsed or Refractory Advanced Renal Cell Carcinoma Following Two or More Prior Systemic Therapies; AVEO Plans to Make FOTIVDA Available to Patients in the U.S. by March 31, 2021 – - Entered Clini...
AVEO Oncology (AVEO) will regain its rights to AV-203 outside of North America, following the voluntary termination of its collaboration and license agreement by CANbridge Life Sciences.AVEO will regain rights to AV-203 in all territories ex-North America, and CANbridge has initiated the proc...
- AVEO Pipeline to Include Global Rights to Three Clinical-Stage and One Commercial-Stage Assets, Including Ficlatuzumab and AV-380 - AVEO Oncology (Nasdaq: AVEO) today announced that it will regain its rights to AV-203 outside of North America, its clinical-stage potent hum...
AVEO Oncology (AVEO) jumps 10% premarket on clinical trial collaboration and supply agreement with Bristol Myers Squibb (BMY) to evaluate Fotivda (tivozanib) in combination with Opdivo (nivolumab) in Phase 3 TiNivo-2 trial in patients with advanced relapsed or refractory renal cell ...
AVEO Oncology (Nasdaq: AVEO) today announced that it has entered into a clinical trial collaboration and supply agreement with Bristol Myers Squibb to evaluate FOTIVDA ® (tivozanib) in combination with OPDIVO ® (nivolumab), Bristol Myers Squibb’s anti-PD-1 thera...
Looking For The Best Health Care Stocks To Buy? 4 Making Waves Now It comes as no surprise that the health care sector would be receiving more attention during a pandemic. By extension, this could also include more investors looking for the top health care stocks now. Why? Well,...
Aveo Oncology (AVEO) trades 1.4% down after hours on closing a $20M drawdown under its earlier announced $45M loan and security agreement with Hercules Capital (HTGC) and its affiliates.This second tranche was made available in connection with the recent U.S. Food and Drug Administration...
AVEO Oncology (Nasdaq: AVEO) today announced that it has completed a drawdown of $20 million under its previously announced $45 million loan and security agreement with Hercules Capital, Inc. (NYSE: HTGC, “Hercules”) and its affiliates. This second tranche was made availab...
Nova LifeStyle (NVFY) +231%.Siebert Financial (SIEB) +63% on Q4 results.Vir Biotechnology (VIR) +60% as its and GSK's COVID-19 antibody drug reduces hospitalization, death by 85%.OrganiGram Holdings (OGI) +40% on cannabis product deal with British American Tobacco.China HGS Rea...
News, Short Squeeze, Breakout and More Instantly...
AVEO Pharmaceuticals Inc. Company Name:
AVEO Stock Symbol:
NASDAQ Market:
SEOUL, South Korea, Jan. 19, 2023 (GLOBE NEWSWIRE) -- LG Chem, Ltd. (“LG Chem”) (KOSPI: 051910) today announced that it has completed its previously announced acquisition of AVEO Oncology (“AVEO”), a commercial stage, oncology-focused biopharmaceutical company committe...
BOSTON, Jan. 05, 2023 (GLOBE NEWSWIRE) -- AVEO Oncology (“AVEO”) (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer, announced that at a special meeting of stockholders ...
BOSTON, Jan. 03, 2023 (GLOBE NEWSWIRE) -- AVEO Oncology (“AVEO”) (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer, reminds all AVEO stockholders to vote before AVEO...